Published in Cancer Weekly, January 18th, 2005
After several informal meetings with CMS following the approval of Plenaxis (abarelix for injectable suspension), PRAECIS filed a formal request with CMS for an NCD in order to ensure both consistent coverage nationwide for Plenaxis as a new class of hormonal therapy for the treatment of advanced symptomatic prostate cancer and compliance with its risk management program, known as the Plenaxis user safety (PLUS) program.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.